Fewer than 1 in 1,000 US adolescents receive gender-affirming 
		medications, researchers find
		
		 
		Send a link to a friend  
 
		
		
		 [January 07, 2025] 
		By CARLA K. JOHNSON 
		
		As U.S. lawmakers debate issues around health care for transgender 
		youth, it’s been difficult to determine the number of young people 
		receiving gender-affirming medications, leaving room for exaggerated and 
		false claims. 
		 
		Now, a medical journal has published the most reliable estimate yet and 
		the numbers are low, reflecting more clearly on medical practices now 
		being weighed by the U.S. Supreme Court. 
		 
		Fewer than 1 in 1,000 U.S. adolescents with commercial insurance 
		received gender-affirming medications — puberty blockers or hormones — 
		during a recent five-year period, according to the study released 
		Monday. 
		 
		At least 26 states have adopted laws restricting or banning 
		gender-affirming medical care for transgender minors, and most of those 
		states face lawsuits. A decision by the Supreme Court in a Tennessee 
		case is expected later this year. President-elect Donald Trump has 
		promised to roll back protections for transgender people. 
		 
		“We are not seeing inappropriate use of this sort of care," said lead 
		author Landon Hughes, a Harvard University public health researcher. 
		“And it’s certainly not happening at the rate at which people often 
		think it is.” 
		 
		The researchers analyzed a large insurance claims database covering more 
		than 5 million patients ages 8 to 17. 
		 
		Only 926 adolescents with a gender-related diagnosis received puberty 
		blockers from 2018 through 2022. During that time, 1,927 received 
		hormones. The findings, published in JAMA Pediatrics, suggest that fewer 
		than 0.1% of all youth in the database received these medications. 
		 
		The researchers found that no patients under age 12 were prescribed 
		hormones, an indication that doctors are appropriately cautious about 
		when to start such treatments, Hughes said. 
		 
		[to top of second column] 
			 | 
            
             
            
			  
             A vial of testosterone is prepared for injection at a home in 
			Florida, on May 29, 2023. (AP Photo/Laura Bargfeld) 
            
			
			  “I hope that our paper cools heads 
			on this issue and ensures that the public is getting a true sense of 
			the number of people who are accessing this care,” he said. 
			 
			The database included insurance plans in all 50 states, but did not 
			include youth covered by Medicaid, the federal-state health 
			insurance program for low-income people. 
			 
			The study did not look at surgeries among transgender adolescents. 
			Other researchers have found those procedures are extremely rare 
			among young people. 
			 
			Not all transgender youth proceed with medical treatments, said Dr. 
			Scott Leibowitz, co-lead author of the adolescent standards of care 
			for the World Professional Association for Transgender Health, a 
			leading transgender health group. 
			 
			Transgender adolescents “come to understand their gender at 
			different times and in different ways,” he said, noting that the 
			best care should include experts in adolescent identity development 
			who can work with families to help figure out what’s appropriate for 
			each young person. 
			 
			Leibowitz, who has worked in gender clinics in several U.S. cities, 
			said the study “adds to the growing evidence base about best 
			practices when serving transgender and gender diverse youth.” 
			
			
			All contents © copyright 2024 Associated Press. All rights reserved  |